论文部分内容阅读
血管生成素(angiogenin,ANG)属脊椎动物特异的核糖核酸酶A超家族第5个成员,是一种分泌型核糖核酸酶,在人类前列腺癌高表达.ANG在前列腺癌的上皮细胞和内皮细胞转位入核,通过刺激r RNA生物合成而介导肿瘤血管新生、癌细胞存活及增殖,从而促进前列腺癌的进程.ANG刺激r RNA合成不仅为前列腺内皮细胞发生癌变所必需,也是前列腺癌细胞不依赖雄激素生长所必需.动物实验证明,各种针对ANG的拮抗剂,包括抑制其核转位、功能和活性的抑制剂均可抑制前列腺癌.现已明确ANG的作用不依赖雄激素,从而为ANG作为去势(即睾丸切除)抗性前列腺癌(castration resistant prostate cancer)的治疗靶标提供了坚实的理论基础.
Angiogenin (ANG) belongs to the fifth member of the vertebrate-specific A-type family of ribonucleases and is a secreted ribonuclease that is overexpressed in human prostate cancer.ANG is associated with epithelial cells and endothelial cells in prostate cancer Translocation into the nucleus, through the stimulation of r RNA biosynthesis and mediated tumor angiogenesis, cancer cell survival and proliferation, thereby promoting the progress of prostate cancer.ANG stimulating RNA synthesis is not only necessary for the occurrence of prostate endothelial cell carcinogenesis, but also prostate cancer cells Independent of androgen growth.An animal experiments show that a variety of antagonists of ANG, including inhibition of its nuclear translocation, function and activity of inhibitors can inhibit prostate cancer.It has been clear that the role of ANG is not dependent on androgen, Thus providing a solid rationale for ANG as a therapeutic target for castration resistant prostate cancer.